Product Description
Mechanisms of Action: GnRH Agonist
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Topical, Nasal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | European Medicines Agency | Ireland | Norway | Poland
Approved Indications: None
Known Adverse Events: None
Company: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dwarfism|Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00080756 |
NCI-2011-00975 | P2 |
Active, not recruiting |
Breast Cancer |
2024-09-15 |
2024-08-29 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT00001190 |
83-CH-0199 | P2 |
Completed |
Dwarfism |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/01/2024 |
PubMed |
GnRH analogs induce a LH peak and increase pregnancy per timed-AI in ewes. |
|
08/01/2023 |
PubMed |
Correction: The use of a 4.7 mg deslorelin slow release implant in male dogs in the field. |
|
07/27/2023 |
PubMed |
Effect of GnRH agonist (deslorelin) on reproductive activity in captive female veiled chameleons (Chamaeleo calyptratus). |